In other prostate cancer news UCLA had a good announcement this week combining ultrasound with MRI capabilities with biopsies as this way the path can be guided instead of a “blind” tissue sample being taken. Anytime there’s more visibility to aim at a target the more accurate the sample should be.
Prostate Cancer Now Detectable by Targeted Biopsy, Potentially Ending 25-year Era of Blind Biopsy
Zytiga is a drug developed for men with late stage prostate cancer and now men don’t have to wait until they begin chemotherapy to begin treatment. The drug is a life extending class that decreases the production of testosterone. BD
Johnson and Johnson Prostate Cancer Drug ZYTIGA™ (Abiraterone Acetate) Receives FDA Approval
The U.S. Food and Drug Administration today expanded the 
approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially approved Zytiga in April 2011 for use in patients whose prostate cancer progressed after treatment with docetaxel, a chemotherapy drug. Zytiga is a pill that decreases the production of male sex hormone testosterone.
In prostate cancer, testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce testosterone production or to block testosterone’s effects. Some men have castration-resistant prostate cancer, meaning the prostate cancer cells continue to grow even with low levels of testosterone.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm
0 comments :
Post a Comment